Gensight Biologics Sa Stock Current Asset
| SIGHT Stock | EUR 0.31 0.01 3.13% |
Gensight Biologics SA fundamentals help investors to digest information that contributes to Gensight Biologics' financial success or failures. It also enables traders to predict the movement of Gensight Stock. The fundamental analysis module provides a way to measure Gensight Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gensight Biologics stock.
Gensight |
Gensight Biologics SA Company Current Asset Analysis
Gensight Biologics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Gensight Biologics SA has a Current Asset of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current asset for all France stocks is 100.0% higher than that of the company.
Gensight Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gensight Biologics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gensight Biologics could also be used in its relative valuation, which is a method of valuing Gensight Biologics by comparing valuation metrics of similar companies.Gensight Biologics is currently under evaluation in current asset category among its peers.
Gensight Fundamentals
| Return On Equity | -1.72 | |||
| Return On Asset | -0.39 | |||
| Operating Margin | (6.59) % | |||
| Current Valuation | 150.19 M | |||
| Shares Outstanding | 46.16 M | |||
| Shares Owned By Insiders | 12.75 % | |||
| Shares Owned By Institutions | 35.65 % | |||
| Price To Book | 50.99 X | |||
| Price To Sales | 33.81 X | |||
| Revenue | 5.28 M | |||
| Gross Profit | 7.71 M | |||
| EBITDA | (25.52 M) | |||
| Net Income | (28.62 M) | |||
| Cash And Equivalents | 44.29 M | |||
| Cash Per Share | 1.06 X | |||
| Total Debt | 12.1 M | |||
| Debt To Equity | 14.40 % | |||
| Current Ratio | 3.65 X | |||
| Book Value Per Share | 0.07 X | |||
| Cash Flow From Operations | (17.14 M) | |||
| Earnings Per Share | (0.68) X | |||
| Target Price | 9.8 | |||
| Number Of Employees | 44 | |||
| Beta | 2.16 | |||
| Market Capitalization | 144.58 M | |||
| Total Asset | 56.65 M | |||
| Z Score | 6.6 | |||
| Net Asset | 56.65 M |
About Gensight Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gensight Biologics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gensight Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gensight Biologics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Gensight Stock Analysis
When running Gensight Biologics' price analysis, check to measure Gensight Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gensight Biologics is operating at the current time. Most of Gensight Biologics' value examination focuses on studying past and present price action to predict the probability of Gensight Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gensight Biologics' price. Additionally, you may evaluate how the addition of Gensight Biologics to your portfolios can decrease your overall portfolio volatility.